2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. EGFR
  4. WGYRGFYC

WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

WGYRGFYC

WGYRGFYC Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

WGYRGFYC Related Antibodies

Top Publications Citing Use of Products

View All EGFR Isoform Specific Products:

View All Isoforms
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer[1].

IC50 & Target

HER2

 

In Vitro

DOTA-WC8 (39-625 nM) binds to HER2 with nanomolar affinity (Kd=61.20 nM) in cell-free SPR assays[1].
[68Ga]Ga-DOTA-WGYRGFYC (37 KBq; 2 h) binds to HER2 in SKBR3 cells, with an IC50 of 51.89 nM[1].
Treatment with 10 μM Pyrotinib reduces the uptake of [68Ga]Ga-DOTA-WGYRGFYC (37 KBq; 15-120 min) by SKBR3 cells, indicating downregulation of HER2 expression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

WGYRGFYC Related Antibodies
In Vivo

[68Ga]Ga-DOTA-WC8 (3.7 MBq; i.v.; single dose) specifically accumulates in HER2-positive SKBR3 tumors with a peak tumor-to-muscle ratio of 4.31 and sensitively detects reduced HER2 expression after pyrotinib treatment[1].
68Ga]Ga-DOTA-WC8 (3.7 MBq; i.v.; single dose) exhibits minimal accumulation in HER2-negative MDA-MB-231 tumors, confirming its HER2 specificity[1].
68Ga]Ga-DOTA-WC8 (i.v.; single dose) has favorable pharmacokinetics in normal mice with rapid distribution and clearance[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (female, 4-5 weeks old)[1]
Dosage: 3.7 MBq
Administration: i.v.; single dose
Result: Exhibited a two-compartment pharmacokinetic profile with a distribution half-life (T1/2α) of 2.898 min and an elimination half-life (T1/2β) of 23.477 min.
Rapidly absorbed by target tumor tissues, while the remaining radiotracer is efficiently cleared from the bloodstream, resulting in an optimal tumor/background ratio (TBR) at early time points postinjection.
Molecular Weight

1051.18

Formula

C51H62N12O11S
Sequence

Trp-Gly-Tyr-Arg-Gly-Phe-Tyr-Cys
Sequence Shortening

WGYRGFYC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

WGYRGFYC Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

WGYRGFYCEGFREpidermal growth factor receptorErbB-1HER1PET radiotracerbreast cancerHER2human epidermal growth factor receptor 2renal clearancetumor tissuesSKBR3 cellsnormal miceHER2-positive breast cancer cellsMDA-MB-231 tumorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
WGYRGFYC
Cat. No.:
HY-P11590
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.